Cointime

Download App
iOS & Android

The Use of Blockchain to Fight Drug Counterfeiting in the Pharmaceutical Industry

Drug counterfeiting is a huge problem worldwide. The prevalence of counterfeit drugs is especially problematic in emerging markets, where regulatory controls are often lax, and the demand for cheap medicines is high.

In fact, it is estimated that counterfeit drugs make up 10% of the global market, costing the industry billions of dollars each year. Despite pharmaceutical companies’ best efforts, the booming counterfeiting market is always prepared to outsmart them in a game of cat and mouse. Keeping tabs on suppliers and verifying authentic supply chains has become quite challenging.

From lax regulation to global trends, the challenges of counterfeit drugs are ever evolving. The pharmaceutical industry feels this impact as healthcare costs rise worldwide; drug counterfeiting could soon become an epidemic if anti-counterfeit strategies aren’t implemented quickly and effectively. As globalization continues to open new markets with increased demand for pharmaceuticals, we must intervene before these nefarious practices spiral out of control.

But what if there were a way to fight back against these counterfeiters? That’s where blockchain comes in.

Infusing Blockchain in the Pharmaceutical Industry

The health sector has been abuzz with the news of blockchain technology coming to revolutionize pharmaceuticals — and its potential continues to drive widespread excitement as trials continue.

Blockchain technology is the ultimate data protector, offering a foolproof system against malicious hacking and corruption. Its decentralized network uses a secure sharing protocol so only authorized parties can access valuable information about products throughout their entire supply chain journey — from origin to consumer — ensuring that drugs stay safe in transit.

Blockchain is an Ideal Technology for Pharmaceutical Track and Trace

Blockchain is shaking up healthcare, allowing drug manufacturers to create a secure ecosystem where data security and quality are top-notch. Everyone involved can easily access the necessary information — never before has it been so easy or promising for healthcare professionals to benefit from such a revolutionary technology.

With the addition of serial numbers to a blockchain, products get an unchanging identity. This is then kept safe through two hallmarks of blocks — decentralization and checksums. Firstly, all involved parties must sign off on any changes made while heightened levels of accuracy are enabled by cryptographic hash functions that mean alterations can never be reversed.

This platform provides a safe and secure way to get pharmaceuticals and carry out transactions. Buyers, sellers, manufacturers — everyone can experience an expedited process free from unnecessary intermediaries. Traceability is guaranteed, so you won’t have to worry about unexpected changes.

Data Security

Blockchain technology provides a safe haven for safeguarding patients’ medical records. It keeps the data secure and grants only those with permission access to confidential information, ensuring people’s rights aren’t compromised. In addition, it helps combat counterfeit drugs by offering fair pricing that leaves no room for deception! The smart contracts on its permissioned blockchain are explicitly designed to prevent shady actors from accessing sensitive patient details.

Vendor credentialing

Blockchain technology provides rigorous vendor credentialing of drug suppliers to ensure patients receive the best medication quality and safety. This vital step verifies their trustworthiness before any purchases are made — ensuring the drugs they provide meet even health ministry standards.

Buyer assurance

Blockchain technology has given consumers the power to verify a drug’s authenticity with just one scan. Combining QR codes, RFID, and GPS tech makes it easier than ever for companies to identify counterfeit products. As a bonus, buyers can now check product history before purchasing — giving them peace of mind that what they’re getting is genuine merchandise.

Tracing and tracking

Thanks to blockchain technology, supply chain tracing and tracking have reached the next level. The origin of drugs can easily be identified along with a complete list of designated destinations each item is likely to pass through. Software-facilitated decentralization ensures smooth sailing while maintaining high product quality throughout the entire process — now that’s something worth celebrating.

Transparency

By leveraging the public ledger of blockchain tech, all parties have crystal-clear visibility throughout the drug supply chain. So no one needs to worry about a sudden change during transit as everyone involved in the supply process is ‘in the know.’ Everyone has access to essential product information, and any changes during shipping or receiving can be made with a few clicks. With this system in place, counterfeit drugs don’t stand a chance.

Closing Thoughts

The pharmaceutical industry is jumping on the blockchain bandwagon and ushering in a new era of drug serialization that is much more effective than its predecessors. From El Salvador legalizing Bitcoin as a legal tender to World Health Organization giving their support, it’s clear that this groundbreaking technology isn’t going anywhere anytime soon! With features like anonymity, decentralization, tamper-proofing, and transparency, efficient tracking of drugs will help end patient health risks for good.

Comments

All Comments

Recommended for you

  • A Total of 37,212.18 DMD Permanently Burned Over the Past 7 Days

    July 9, 2026 — According to the latest on-chain data released by DMDAO, a total of 37,212.18 DMD has been permanently burned over the past seven calendar days through the protocol's predefined trading and wealth management burn mechanisms.

  • Whale Transfers 1,133 BTC to Coinbase Prime, Valued at $71.48 Million

    According to Onchain Lens monitoring, a whale transferred 1,133 BTC from Coinbase to Coinbase Prime through an intermediary wallet, valued at $71.48 million.

  • U.S. AI Chip Stocks Decline Before Market Open, Intel Falls Over 3%

    On July 7, U.S. AI chip stocks experienced widespread declines before the market opened. Intel dropped over 3%, while AMD, Qualcomm, and NXP fell more than 2%. TSMC, Broadcom, and Tesla decreased by over 1%, and NVIDIA declined by 0.7%.

  • China's Central Bank Increases Gold Reserves for the 20th Consecutive Month

    As of the end of June, China's gold reserves stood at 75.44 million ounces (approximately 2,346.446 tons), an increase of 480,000 ounces (about 14.93 tons) from the end of May, which reported 74.96 million ounces (approximately 2,331.52 tons). This marks the 20th consecutive month of gold accumulation.

  • China's Foreign Exchange Reserves in June at $341.6262 Billion

    On July 7, China's foreign exchange reserves for June stood at $341.6262 billion, a decrease of $26 billion from the end of May, representing a decline of 0.75%, with expectations set at $343.2 billion.

  • U.S. Storage Stocks Drop Pre-Market, SanDisk and Micron Down Over 4%

    On July 7, U.S. storage concept stocks collectively fell in pre-market trading. Western Digital dropped over 5%, SanDisk and Micron Technology fell over 4%, Seagate Technology declined over 3%, Rambus fell over 2%, and SMI fell over 1%.

  • U.S. Stocks in Optical Communication Sector Drop Pre-Market

    On July 7, stocks in the optical communication sector of the U.S. market collectively fell pre-market. Astera Labs dropped over 4%, while Marvell Technology, Credo Technology, and AXT Inc. fell more than 3%. Tower Semiconductor, MaxLinear, Corning, Applied Optoelectronics, GlobalFoundries, Lumentum, and Qorvo all declined by more than 2%. Coherent, Nokia, Amphenol, and Broadcom dropped over 1%.

  • Pre-market Decline in U.S. Storage Stocks

    In pre-market trading, U.S. storage concept stocks experienced a widespread decline, with Micron Technology falling by 4.8%, SanDisk dropping over 4%, Corning down more than 2%, and Intel decreasing by over 3%.

  • Two Departments: Support for Reinsurance Institutions to Increase Capital and Issue Supplementary Capital Tools

    On July 7, the National Financial Supervision and Administration Bureau and the Shanghai Municipal Government released several measures to accelerate the construction of the Shanghai International Reinsurance Center. Among these measures, they proposed to enhance the quality and efficiency of the reinsurance industry, support reinsurance institutions in increasing capital and expanding shares, and issuing supplementary capital tools to improve the capacity for internal capital accumulation and external capital supplementation, thereby strengthening the reinsurance industry's capabilities. The initiative aims to guide the insurance industry to focus on major national projects, strategic emerging industries, and livelihood security, consolidating insurance and reinsurance underwriting capabilities to enhance risk protection levels. It also supports reinsurance institutions in leveraging their professional technical advantages to assist the insurance industry in reducing risk.

  • Sources: Saudi Arabia Plans to Expand Oil Pipeline to Red Sea, Increasing Capacity by 2 Million Barrels Daily to Bypass Strait of Hormuz

    On July 7, five informed sources revealed that Saudi Arabia is considering expanding the crude oil pipeline capacity to its western coast on the Red Sea, allowing Saudi Arabia and its neighbors to transport more oil without passing through the Strait of Hormuz. This east-west pipeline, built in the early 1980s, has gained strategic importance since the outbreak of the Iran war in February and the disruption of shipping in the Strait of Hormuz. The pipeline can deliver up to 7 million barrels of crude oil per day to the Red Sea port. The CEO of Saudi Aramco stated in May that approximately 2 million barrels are supplied to west coast refineries, while about 5 million barrels are for export. Sources indicate that Saudi Arabia is in preliminary discussions with some neighboring countries regarding the pipeline expansion, aiming to add about 2 million barrels of pipeline capacity per day. It remains unclear whether Aramco's planned expansion involves upgrading existing infrastructure or constructing new pipelines. One source mentioned that the expansion plan also includes a smaller refined oil pipeline. Two sources indicated that the expansion scale could range from 1 million to 2 million barrels per day, with refined oil also being considered. Another source stated that the project would take several years and cost billions of dollars, requiring adjustments to Saudi crude pricing mechanisms.